Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Protagonist Therapeutics stock
Learn how to easily invest in Protagonist Therapeutics stock.
Protagonist Therapeutics is a biotechnology business based in the US. Protagonist Therapeutics shares (PTGX) are listed on the NASDAQ and all prices are listed in US Dollars. Protagonist Therapeutics employs 122 staff and has a trailing 12-month revenue of around $35.2 million.
How to buy Protagonist Therapeutics stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – PTGX. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Easy to use platform with low fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
Protagonist Therapeutics stock price (NASDAQ: PTGX)Use our graph to track the performance of PTGX stocks over time.
Protagonist Therapeutics shares at a glance
|Latest market close||$14.33|
|52-week range||$6.91 - $29.25|
|50-day moving average||$10.17|
|200-day moving average||$9.51|
|Wall St. target price||$33.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.58|
Buy Protagonist Therapeutics stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Protagonist Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Protagonist Therapeutics price performance over time
|1 week (2023-01-31)||7.83%|
|1 month (2023-01-06)||22.79%|
|3 months (2022-11-07)||84.90%|
|6 months (2022-08-05)||25.04%|
|1 year (2022-02-07)||-48.82%|
|2 years (2021-02-05)||-35.97%|
|3 years (2020-02-07)||74.33%|
|5 years (2018-02-07)||17.88|
Protagonist Therapeutics financials
|Revenue TTM||$35.2 million|
|Gross profit TTM||$27.4 million|
|Return on assets TTM||-25.15%|
|Return on equity TTM||-45.39%|
|Market capitalisation||$703 million|
TTM: trailing 12 months
Protagonist Therapeutics share dividends
We're not expecting Protagonist Therapeutics to pay a dividend over the next 12 months.
Protagonist Therapeutics share price volatility
Over the last 12 months, Protagonist Therapeutics's shares have ranged in value from as little as $6.91 up to $29.245. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Protagonist Therapeutics's is 2.0806. This would suggest that Protagonist Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Protagonist Therapeutics overview
Protagonist Therapeutics, Inc. , a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. .
Protagonist Therapeutics in the news
Protagonist Therapeutics (PTGX) Moves 10.7% Higher: Will This Strength Last?
Are Investors Undervaluing Protagonist Therapeutics, Inc. (NASDAQ:PTGX) By 50%?
Frequently asked questionsWhat percentage of Protagonist Therapeutics is owned by insiders or institutions?
Currently 1.455% of Protagonist Therapeutics shares are held by insiders and 100.147% by institutions. How many people work for Protagonist Therapeutics?
Latest data suggests 122 work at Protagonist Therapeutics. When does the fiscal year end for Protagonist Therapeutics?
Protagonist Therapeutics's fiscal year ends in December. Where is Protagonist Therapeutics based?
Protagonist Therapeutics's address is: 7707 Gateway Boulevard, Newark, CA, United States, 94560-1160 What is Protagonist Therapeutics's ISIN number?
Protagonist Therapeutics's international securities identification number is: US74366E1029 What is Protagonist Therapeutics's CUSIP number?
Protagonist Therapeutics's Committee on Uniform Securities Identification Procedures number is: 74366E102
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert